These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12735913)

  • 21. Neuroleptic malignant syndrome complicating levodopa withdrawal.
    Reutens DC; Harrison WB; Goldswain PR
    Med J Aust; 1991 Jul; 155(1):53-4. PubMed ID: 2067442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.
    Toru M; Matsuda O; Makiguchi K; Sugano K
    J Nerv Ment Dis; 1981 May; 169(5):324-7. PubMed ID: 6111584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 77-year-old man with Parkinson's disease and hyperthermia.
    Madigan EJ
    J Emerg Nurs; 2008 Jun; 34(3):229-30. PubMed ID: 18558256
    [No Abstract]   [Full Text] [Related]  

  • 24. [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease].
    Yamawaki Y; Ogawa N
    Rinsho Shinkeigaku; 1991 Jan; 31(1):62-7. PubMed ID: 2044308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
    Clarke CE
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):510-1; author reply 511. PubMed ID: 14966183
    [No Abstract]   [Full Text] [Related]  

  • 26. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication.
    Stotz M; Thümmler D; Schürch M; Renggli JC; Urwyler A; Pargger H
    Br J Anaesth; 2004 Dec; 93(6):868-71. PubMed ID: 15377584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Case of Total Parenteral Nutrition Precipitated Neuroleptic Malignant-Like Syndrome in Advanced Stage Parkinson Disease.
    Li W; Saweris M; Madhira B
    Am J Ther; 2018; 25(5):e606-e607. PubMed ID: 28731860
    [No Abstract]   [Full Text] [Related]  

  • 28. Preface: Malignant syndrome in Parkinson's disease.
    Narabayashi H; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S1. PubMed ID: 12735908
    [No Abstract]   [Full Text] [Related]  

  • 29. [Increase in serum creatine phosphokinase following administration of talipexole hydrochloride].
    Osumi E; Imai T
    Rinsho Shinkeigaku; 2000 Oct; 40(10):1041-3. PubMed ID: 11296371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
    Fiore S; Persichino L; Anticoli S; De Pandis MF
    Acta Biomed; 2014 Dec; 85(3):281-4. PubMed ID: 25567468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The parkinsonism-hyperpyrexia syndrome.
    Newman EJ; Grosset DG; Kennedy PG
    Neurocrit Care; 2009; 10(1):136-40. PubMed ID: 18712508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.
    Gibb WR; Griffith DN
    Postgrad Med J; 1986 Jan; 62(723):59-60. PubMed ID: 3797365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
    Mizuno Y; Shimoda S; Origasa H
    J Neural Transm (Vienna); 2018 Jan; 125(1):35-43. PubMed ID: 28091751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
    Ogawa N; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Yanagisawa N
    Eur Neurol; 1997; 38 Suppl 2():37-49. PubMed ID: 9387802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period.
    Mizuta E; Yamasaki S; Nakatake M; Kuno S
    Neurology; 1993 May; 43(5):1048-9. PubMed ID: 7605396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report.
    Wu YF; Kan YS; Yang CH
    Gen Hosp Psychiatry; 2011; 33(3):301.e7-8. PubMed ID: 21601731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant syndromes: current advances.
    Tao M; Li J; Wang X; Tian X
    Expert Opin Drug Saf; 2021 Sep; 20(9):1075-1085. PubMed ID: 33866917
    [No Abstract]   [Full Text] [Related]  

  • 39. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
    Bonnici A; Ruiner CE; St-Laurent L; Hornstein D
    Ann Pharmacother; 2010 Sep; 44(9):1504-7. PubMed ID: 20628041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.